Role of transarterial chemoembolization before liver resection for hepatocarcinoma
Role of transarterial chemoembolization before liver resection for hepatocarcinoma
复制标题
DOI：
10.1053/jlts.2000.8312
复制
发表时间：
2000-09-01
影响因子：
4.6
通讯作者：
Faccioli, AM
中科院分区：
文献类型：
--
作者：
Gerunda, GE;Neri, D;Faccioli, AM
本研究的目的是阐明肝切除术（LR）前化疗栓塞（TACE）是否可以减少术后肝细胞癌（HCC）复发，提高无病生存和总生存，对89例肿瘤期（TNM） I-II型HCC患者进行LR评估。根据患者的居住地，前瞻性地将患者分配到单独LR或TACE加LR。非本地患者20例（24%）行LR，本地患者69例（77.5%）行TACE + LR。在TACE手术后，只有20名患者（29%）可以确认肿瘤分期，然后接受LR。手术死亡率为0%，但在TACE-LR组中，3例患者在术后2至5个月内死于肝衰竭。早期复发(
The aim of this study was to clarify whether chemoembolization (TACE) before liver resection (LR) can reduce postoperative hepatocellular carcinoma (HCC) recurrence and improve disease-free and overall survival, Eighty-nine patients with tumor-stage (TNM) I-II HCC were evaluated for LR. Patients were prospectively allocated to LR alone or TACE plus LR based on their place of residence. Twenty nonlocal patients (24%) were selected for LR, while 69 (77.5%) local patients were selected for TACE plus LR. Following TACE, the tumor stage could be confirmed in only 20 patients (29%) who then underwent LR. Operative mortality was 0%, but in the TACE-LR group, 3 patients died of liver failure between 2 and 5 months after surgery. Early recurrence (